Prohibition Partners

Prohibition Partners · Free weekly briefing

International Cannabis Weekly

The week’s global cannabis news, read through the analyst’s lens — one sentence per story, sourced.

413

7 regions34 stories20 publishers14 countries

← №412All issues414

Top story

Cannabis stocks hit highest point this year on Trump rescheduling hopes

Cannabis stocks across North America have skyrocketed to their highest point so far this year, despite a lukewarm promise from the US President on cannabis rescheduling. As Business of Cannabis reported earlier this week, on Monday, President Trump publicly addressed the long-stalled rescheduling project for the first time since taking office.

Business of CannabisUSCABusiness & Investment

  1. 01

    German health insurers move to stop covering flower costs

    Business of CannabisDEMedical

  2. 02

    High Tide to acquire majority stake in Remexian Pharma GmbH

    StratCannDEBusiness & Investment

United States

6 stories
  • Federally funded study shows cannabis use helps veterans reduce PTSD symptoms on use days

    USHealth & Sciencelink no longer available

  • President Trump says decision on cannabis legalisation will be left to individual states

    USRegulationlink no longer available

  • Oklahoma cannabis activists launch interactive map for 2026 ballot petition locations

    USAdult-uselink no longer available

  • Cresco Labs has posted $164 million in new revenue for the second quarter of 2025

    USBusiness & Investmentlink no longer available

  • New York cannabis dispensaries located near schools have been permitted to remain open

    USRegulationlink no longer available

  • Michigan has signed MOU with Bay Mills Indian Community for cannabis cooperation

    USRegulationlink no longer available

Never miss an issue

International Cannabis Weekly in your inbox every week — the global developments that move the market, with the data behind them.

From the research library

Global Medical Cannabis Market Review

14 key international markets, 2025–2030. Sizing, forecasts and regulatory outlook.

From £1,265

View report